Research at Washington University School of Medicine in St. Louis has found that psilocybin disrupts critical brain networks involved in introspective thinking.

The study was led by Subha Subramanian, Demetrius Perry, and Benjamin P. Kay.

This disruption of brain areas provides insight into psilocybin's potential therapeutic benefits for mental illnesses like depression and PTSD.

Researchers visualized the impact of psilocybin on functional brain networks and correlated changes with participants' subjective experiences.

The findings show promise for personalized treatment approaches.

Psilocybin is not FDA-approved for any condition, and self-medication without professional supervision can be risky.